Catalytic Transamidation Reactions Compatible with Tertiary Amide Metathesis under Ambient Conditions
作者:Nickeisha A. Stephenson、Jiang Zhu、Samuel H. Gellman、Shannon S. Stahl
DOI:10.1021/ja8094262
日期:2009.7.29
present study reveals that simple zirconium- and hafnium-amido complexes are highly efficient catalysts for equilibrium-controlled transamidation reactions between secondary amines and tertiary amides. In a number of cases, transamidation proceeds rapidly at room temperature. We find that these new catalysts are sufficiently active to promote the metathesis of tertiary amides, which arises from successive
[EN] PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSES DE PYRROLOTRIAZINE SERVANT D'INHIBITEURS DE KINASES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2005066176A1
公开(公告)日:2005-07-21
The present invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
The present invention provides compounds of formula I
and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
[EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
申请人:NOVARTIS AG
公开号:WO2006018284A1
公开(公告)日:2006-02-23
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.